-
Sales Success Comes With Side Effects For Drug Maker BeiGene
Thursday, August 10, 2023 - 9:37am | 1302Read More...Key Takeaways: Global sales of BeiGene’s anti-tumor drug zanubrutinib more than doubled to $308 million (2.22 billion yuan) in the quarter BeiGene was slapped with a patent lawsuit by U.S. rival AbbVie in June, and suffered another blow to its global ambitions in July when Novartis pulled...
-
Celgene Reports Second-Quarter Results, Highlights 'Outstanding' 2016 Performance
Thursday, July 28, 2016 - 8:36am | 397Read More...Shares of Celgene Corporation (NASDAQ: CELG) were trading higher by 0.43 percent at $108.11 after the company reported its second-quarter results. Celgene said it earned $1.44 per share in the second quarter on revenue of $2.74 billion. Wall Street analysts were expecting the company to earn $1.39...
-
Celgene's EPS Contain 'Few Surprises,' Baird Says
Friday, January 30, 2015 - 1:05pm | 311Read More...Celgene Corporation (NASDAQ: CELG) reported earnings on Thursday, and Baird analysts provided some commentary. For the fourth quarter of 2014, the company posted non-GAAP EPS of $1.01, (versus consensus of $0.99, and Baird’s $1.01), and adjusted EPS for the full fiscal 2014 of $3.71...
-
Market Wrap For January 7: Markets Reverse 3-Day Slump
Tuesday, January 7, 2014 - 5:39pm | 2743Read More...For the first time in the new year, markets ended the day on a positive note. While it is only a few days in, markets appear to have started off 2014 on uncertain footing. Investors and traders found some positives in the U.S. trade deficit which fell to its lowest level in four years, an...
